Valneva (NASDAQ:VALN) Posts Quarterly Earnings Results, Misses Expectations By $0.17 EPS

Valneva (NASDAQ:VALN) posted its quarterly earnings data on Friday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.17), Zacks reports. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%.The company had revenue of $39.37 million for the quarter, compared to the consensus estimate of $43.15 million.

Valneva Stock Up 26.2%

Shares of NASDAQ VALN traded up $1.48 during mid-day trading on Friday, hitting $7.13. 2,871,568 shares of the stock traded hands, compared to its average volume of 69,117. The company has a market cap of $676.57 million, a price-to-earnings ratio of -3.81 and a beta of 1.77. The stock has a fifty day moving average price of $5.21 and a 200-day moving average price of $6.92. Valneva has a 52 week low of $4.75 and a 52 week high of $12.25. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.60 and a current ratio of 2.14.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on VALN shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Valneva in a report on Thursday, June 18th. TD Cowen initiated coverage on Valneva in a report on Tuesday. They set a “buy” rating and a $12.00 target price for the company. Guggenheim set a $11.00 price objective on Valneva in a research report on Thursday, April 16th. Wall Street Zen upgraded shares of Valneva from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. Finally, The Goldman Sachs Group lowered shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target for the company. in a report on Wednesday, April 22nd. Four analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $11.98.

Hedge Funds Weigh In On Valneva

A number of institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd bought a new stake in shares of Valneva in the 4th quarter worth approximately $94,000. JPMorgan Chase & Co. bought a new stake in Valneva during the 3rd quarter valued at about $124,000. Finally, Marex Group plc purchased a new position in Valneva in the second quarter worth about $64,000. Institutional investors own 11.39% of the company’s stock.

Key Headlines Impacting Valneva

Here are the key news stories impacting Valneva this week:

• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s marketing authorization application for their six-valent Lyme disease vaccine candidate, PF-07307405. The validation allows the EMA to begin its formal assessment, a significant step toward potential approval and commercialization. The vaccine is being developed in partnership with Pfizer, with regulatory decisions potentially targeted within the next year. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: Investor attention is increasing around the potential Lyme vaccine market. Reports said the European Union will study the candidate, which could address an unmet need as Lyme disease cases rise and no broadly available human vaccine is currently marketed. EU to study potential vaccine for Lyme disease: companies
• Neutral Sentiment: TD Cowen initiated research coverage on Valneva. New analyst coverage may improve visibility, but the article did not provide a rating or price target that would establish a clear trading signal. Valneva Research Coverage Started at TD Cowen
• Negative Sentiment: Valneva’s second-quarter earnings missed expectations: the company reported a loss of $0.40 per share versus a consensus loss of $0.23, while revenue of $39.37 million fell short of the $43.15 million estimate. The company continues to report substantial losses, reflected in its negative net margin and return on equity. Valneva Earnings Results
• Neutral Sentiment: Management reaffirmed its 2026 financial outlook while emphasizing a strategic focus on commercial execution and the Lyme vaccine program. The guidance provides some visibility, but profitability and the timing of potential Lyme vaccine revenue remain uncertain. Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.